Last reviewed · How we verify
Infusion of NEXI-001 T Cells
Infusion of NEXI-001 T Cells is a Biologic drug developed by NexImmune Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | Infusion of NEXI-001 T Cells |
|---|---|
| Sponsor | NexImmune Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT (PHASE1, PHASE2)
- Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infusion of NEXI-001 T Cells CI brief — competitive landscape report
- Infusion of NEXI-001 T Cells updates RSS · CI watch RSS
- NexImmune Inc. portfolio CI
Frequently asked questions about Infusion of NEXI-001 T Cells
What is Infusion of NEXI-001 T Cells?
Infusion of NEXI-001 T Cells is a Biologic drug developed by NexImmune Inc..
Who makes Infusion of NEXI-001 T Cells?
Infusion of NEXI-001 T Cells is developed by NexImmune Inc. (see full NexImmune Inc. pipeline at /company/neximmune-inc).
What development phase is Infusion of NEXI-001 T Cells in?
Infusion of NEXI-001 T Cells is in Phase 1.
Related
- Manufacturer: NexImmune Inc. — full pipeline
- Compare: Infusion of NEXI-001 T Cells vs similar drugs
- Pricing: Infusion of NEXI-001 T Cells cost, discount & access